GNMX - Aevi Genomic Medicine, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development28,35615,4448,253
Selling General and Administrative13,52312,95410,686
Non Recurring-8,1708,170
Total Operating Expenses---
Operating Income or Loss-41,879-36,568-18,939
Income from Continuing Operations
Total Other Income/Expenses Net151586
Earnings Before Interest and Taxes-41,864-36,567-18,353
Interest Expense241,40868
Income Before Tax-41,888-37,975-18,421
Income Tax Expense161712
Minority Interest---
Net Income From Continuing Ops-41,904-37,992-18,433
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-41,904-37,992-18,433
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-41,904-37,992-18,433